The delivery of whole-cell cancer vaccines has been accomplished using a PLGA matrix containing tumor lysate as the source of tumor antigens, granulocyte macrophage colony-stimulating factor (GM-CSF) for recruitment of DCs in situ, and CpG for DC activation. Here, CSF2 is linked to neoplasm.